CCR5 antagonist maraviroc's effect to osteoclasts in huma
Not Applicable
- Conditions
- HIV-1 infection, AIDS
- Registration Number
- JPRN-UMIN000006266
- Lead Sponsor
- ational Center for Global Health and Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
- Those who are not suited for maraviroc (whose HIV strain to be CXCR4 tropism) - Others who the principle investigator physician considered to be excluded
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Bone metabolism and density evaluation by - Bone and chemokine markers (DPD, NTX, CTX, TRACP, BAP, osteocalcin, MIP-1alpha, MIP-1beta and RANTES) and - DEXA
- Secondary Outcome Measures
Name Time Method - Other infections: HBV, HCV, RPR, TPHA - HIV treatment markers: CD4, CD8, CD4/CD8, HIV-RNA - HAART regimens and start dates - Other medications: antibiotics, anticoagulants, antiplatelets, NSAID, steroids - Past medical history - HIV risk behaviors, age, sex